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Background: Signal transducers and activators of transcription (STAT) proteins are critical transcription factor that
are aberrantly activated in various types of malignancies, including renal cell carcinoma (RCC).
Methods: We investigated the effect of resveratrol (RES), an edible polyphenol phytoalexin on STAT3 and STAT5
activation cascade in both Caki-1 and 786-O RCC cell lines.
Results: We found that RES suppressed both constitutive STAT3 (tyrosine residue 705 and serine residue 727) and
STAT5 (tyrosine residue 694 and 699) activation, which correlated with the suppression of the upstream kinases
(JAK1, JAK2, and c-Src) in RCC. Also, RES abrogated DNA binding capacity and nuclear translocation of these two
transcription factors. RES-induced an increased expression of PTPε and SHP-2 and the deletion of these two genes
by small interfering RNA abolished the ability of RES to inhibit STAT3 activation, suggesting the critical role of both
PTPε and SHP-2 in its possible mechanism of action. Moreover, RES induced S phase cell cycle arrest, caused
induction of apoptosis, loss of mitochondrial membrane potential, and suppressed colony formation in RCC. We
also found that RES downregulated the expression of STAT3/5-regulated antiapoptotic, proliferative, and metastatic
gene products; and this correlated with induction of caspase-3 activation and anti-invasive activity. Beside, RES
potentiated sorafenib induced inhibitory effect on constitutive STAT3 and STAT5 phosphorylation, apoptotic effects
in 786-O cells, and this correlated with down-regulation of various oncogenic gene products.
Conclusion: Overall, our results suggest that RES is a blocker of both STAT3 and STAT5 activation and thus may
exert potential growth inhibitory effects against RCC cells.
Keywords: Resveratrol, STAT3/5, PTPε, SHP-2, Renal cell carcinomaBackground
Signal transducer and activator of transcription (STAT)
proteins initially discovered as latent cytoplasmic tran-
scription factors about two decades ago [1], consist of
seven diverse members,STAT1 to STAT6, STAT5a and
STAT5b [2], that have been found to play a pivotal role* Correspondence: ksahn@khu.ac.kr
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Among the different STATs, STAT3 and STAT5 are
often constitutively active in various human cancers, in-
cluding renal cell carcinoma (RCC) [4–6], and control
the expression of multiple genes involved in initiation,
progression and chemoresistance [7–9]. Once STATs are
activated, it translocates into the nucleus and controls
the transcription of various oncogenic genes [3]. The
phosphorylation is mediated through the activation of
various upstream kinases called Janus activated kinases
(JAKs) [1, 10]. The activation of STAT3 can induce thedistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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tosis inhibitors (bcl-xl, bcl-2, IAP-1/2, and survivin),
cell-cycle regulators (cyclin D1, and cyclin E), and in-
ducers of angiogenesis (MMP-9 and VEGF) [11, 12].
Like STAT3, STAT5 has been also shown to regulate
proliferation and inhibition of apoptosis in several can-
cer cells because cyclin D1 and bcl-xL promoters con-
tain putative STAT5 binding sites [13, 14]. Thus,
identification of novel pharmacological agents which in-
hibit STAT3 and STAT5 activation have promise and
potential in prevention and therapy of cancer [15].
The identification of novel anticancer agents derived
from Mother nature offer a great opportunity to improve
the existing standard of care for RCC and other cancers
[16]. RES (trans 3, 4’, 5-trihydroxystilbene) is a naturally
occurring polyphenol phytoalexin and can be found in
approximately 72 plant species, including grapes, pea-
nuts, red wine and weed Polygonumcuspidatum [17–20].
In plants, RES functions microbiologically as a phyto-
alexin that protects against fungal infections [21, 22].
Preclinical studies demonstrate that RES has been found
to be effective against various types of human cancers
[23]. In addition, previous studies documented it has the
ability to affect tumor initiation and promotion, inhibit
angiogenesis and metastasis, and induce cell cycle arrest
and apoptosis [24–26].
Renal cell carcinoma (RCC) is the most common malig-
nancy of the adult kidney, and the incidence of newly di-
agnosed renal cell carcinoma cases have been steadily
increasing over two decades [27–29]. Unlike many other
cancers, there are few biomarkers and prognosis for RCC
[30], and renal cancer patients display resistance to both
conventional therapy and radiation treatment [31–33].
Hence, the discovery of novel therapeutics or molecular
targeted therapies for RCC remains a priority. Previous re-
ports show high frequency of increased STATs activation
in RCC cells and patient specimens [4, 34, 35]. Because of
the pivotal role of STATs in tumor cell survival, prolifera-
tion, and angiogenesis, we hypothesized that STAT3
and STAT5 could be a novel therapeutic target for
RCC. Thus, in our study, we examined whether RES





phenyltetrazolium bromide (MTT), propidium iodide
(PI), Tris base, glycine, NaCl, sodium dodecylsulfate
(SDS), and bovine serum albumin (BSA) were purchased
from Sigma-Aldrich (St. Louis, MO). RPMI 1640, fetal
bovine serum (FBS), antibiotic-antimycotic mixture,
and LightShift® Chemiluminescent EMSA kit were ob-
tained from Thermo Fisher Scientific Inc. (Waltham,MA). 5’-biotinylated STAT3 and STAT5 was from Bio-
neer Corporation (Daejeon, Korea). Alexa Fluor® 488
donkey anti-rabbit IgG (H + L) antibody, and 0.4 % try-
pan blue vital stain, and TMRE (tetramethylrhodamine,
ethyl ester) were obtained from Life Technologies
(Grand Island, NY). Anti-phospho-STAT3(Tyr705),
anti-phospho-STAT3(Ser727), anti-phospho-JAK1(Tyr1
022/1023), anti-JAK1, anti-phospho-JAK2(Tyr1007/10
08), anti-JAK2, and anti-phospho-Src(Tyr416) anti-
bodies were purchased from Cell Signaling Technology
(Beverly, MA). Anti-STAT3, anti-phospho-STAT5(Tyr
694/Tyr 699), anti-STAT5, anti-Src, anti-PTPε, anti-
SHP-2, anti-bcl-2, anti-bcl-xL, anti-survivin, anti-IAP-
1, anti-IAP-2, anti-COX-2, anti-VEGF, anti-MMP-9
(matrix metalloproteinase-9), anti-caspase-3, anti-cleaved
caspase-3, anti-PARP, anti-cyclin D1, anti-cyclin E, anti-
Bax, anti-p21, anti-p53, anti-β-actin, and horseradish per-
oxidase (HRP)-conjugated secondary antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Annexin V staining kits (ApoScan) were pur-
chased from BioBud (Seoul, Korea). TUNEL (terminal
transferase mediated dUTP-fluorescein nick end label-
ing) assay kit was from Roche Diagnostics GmbH
(Mannheim, Germany).
Cell lines
Human Renal cell carcinoma Caki-1 and 786-O were
obtained from the American Type Culture Collection
(Manassas, VA). Caki-1 and 786-O cells were cultured in
RPMI 1640 medium containing 10 % FBS. Media were
also supplemented with 100 U/ml of penicillin and
100 μg/ml of streptomycin.
Western blotting
Western blot analysis was performed using a method de-
scribed previously [36].
EMSA for STAT3 and STAT5-DNA binding
Electrophoretic mobility shift assay (EMSA) was per-
formed as described previously [36]. The membrane was
detected following manufacturer instructions using Light-
Shift® Chemiluminescent EMSA kit (Waltham, MA).
Immunocytochemistry for STAT3 and STAT5 localization
Immunocytochemistry was performed as described pre-
viously [37].
Reverse transcription polymerase chain reaction (RT-PCR)
Reverse transcription polymerase chain reaction was
performed using a method described previously [38].
Transfection with PTPε and SHP-2 siRNA
Caki-1 and 786-O cells were plated in 6-well plates and
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Fig. 1 RES suppresses phosphorylation of STAT3 and STAT5 in a dose-dependent manner in RCC cells. a The chemical structure of resveratrol
(RES). b and c Caki-1 and 786-O cells (1 × 106 cells/well) were incubated at 37 °C with various indicated concentrations of RES for 6 h. Whole-cell
extracts were prepared, then equal amounts of lysates were analyzed by Western blot analysis using antibodies against p-STAT3(Tyr705), p-
STAT3(Ser727), STAT3, p-STAT5(Tyr694/Tyr699), and STAT5. The results shown here are representative of three independent experiments. d Caki-1
and 786-O cells (1 × 106 cells/well) were incubated at 37 °C with various indicated concentrations of RES for 6 h. After that, nuclear proteins were
extract, equal amounts of lysates were analyzed by Western blot analysis using antibodies against STAT3 and STAT5. The same blots were stripped
and reprobed with Lamin B antibody to verify equal protein loading. The results shown here are representative of three independent experiments. e and
f RES suppresses STAT3 and STAT5 binding activity in Caki-1 and 786-O cells. After Caki-1 and 786-O cells (1 × 106 cells/well) were incubated at 37 °C with
the indicated concentrations of RES for 6 h, analyzed for nuclear STAT3 and STAT5 levels by EMSA. The results shown here are representative of three
independent experiments. g and h RES causes inhibition of translocation of STAT3 and STAT5 to the nucleus. Caki-1 and 786-O cells (3 × 104 cells/well)
were incubated at 37 °C with 50 μM of RES treatment, the cells were fixed and permeabilized. STAT3 and STAT5 (green) was immunostained with rabbit
anti-STAT3 and anti-STAT5 followed by FITC-conjugated secondary antibodies and the nuclei (blue) were stained with DAPI. The third panels show the
merged images of the first and second panels. Scale bar = 100 μm. The results shown are representative of two independent experiments
Kim et al. BMC Nephrology  (2016) 17:19 Page 4 of 13of transfection, 6 μl of Lipofectamin 2000 (Invitrogen,
Carlsbad, CA) were added to 50 nM PTPε and SHP-2
siRNA in a final volume of 1 ml culture medium. After
5 h of transfection, cells were treated with RES for 8 h
and whole-cell extracts were prepared for PTPε, SHP-2,
phospho-STAT3, and STAT3 analysis by Western blot
analysis.
Cell cycle analysis
Cell cycle analysis was performed as described previ-
ously [37].
Annexin V assay
Annexin V assay was performed using a method described
previously [37]
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential assay was performed
using a method described previously [37].
Clonogenic assay
Clonogenic assay was performed as described previ-
ously [39].
Monitoring of cell growth with the RTCA DP instrument
Real-time cell proliferation analysis assay was performed
using a method described previously [39].
Invasion assay
Invasion assay was performed as described previ-
ously [37].
MTT assay
Cell viability was measured by an MTT assay to detect
NADH-dependent dehydrogenase activity [40], as de-
scribed previously [39].
Analysis of drug interactions
Analysis of drug interactions were performed using a
method described previously [41]Statistical analysis
Statistical analysis was performed by Student’s t-test and
one way analysis of variance, (ANOVA). A p value of less
than 0.05 was considered statistically significant.
Results
RES down-regulates constitutive STAT3 and STAT5
phosphorylation in renal cell carcinoma
We first tested whether RES (structure of resveratrol,
Fig. 1a) inactivated STAT3 in Caki-1 and 786-O renal
cancer cells. Previous studies have shown that STAT3 is
a key point of convergence of multiple oncogenic signal-
ing pathways [42–44]. The ability of RES to modulate
constitutive STAT3 activation in RCC cells was investi-
gated by Western blot analysis using antibodies which
recognize STAT3 phosphorylation at tyrosine 705 and
serine 727. As shown in Fig.1b, RES inhibited the consti-
tutive activation of STAT3 in both Caki-1 and 786-O
cells in a dose-dependent manner, with maximum inhib-
ition occurring at around 50 μM, but had no effect on
the expression of STAT3 protein (Fig. 1b, third panels).
Whether RES affects the activation of another STAT
family isoform, STAT5 in renal cancer cells was also in-
vestigated. We noticed that RES substantially reduced
constitutive STAT5 activation in both Caki-1 and 786-O
cells, without affecting total STAT5 levels as analyzed by
Western blot analysis (Fig. 1c).
RES reduces STAT3 and STAT5 in nuclei
We tested the effect of RES on STAT3 and STAT5 in
nuclei. As shown by Western blot analysis in Fig. 1d,
RES inhibits nuclear STAT3 and STAT5 in Caki-1 and
786-O cells.
RES inhibits binding capacity of STAT3 and STAT5 to the
DNA
We next determined whether RES can modulate the
DNA-binding ability of STAT3 and STAT5 proteins in
RCC cells. EMSA analysis of nuclear extracts prepared
from Caki-1 and 786-O cells showed that RES reduced
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Fig. 2 Pervanadate reverses the phospho-STAT3 inhibitory effect of RES. a and b Caki-1 and 786-O cells (1 × 106 cells/well) were incubated at 37 °C with
various indicated concentrations of RES for 6 h. Whole-cell extracts were prepared, then equal amounts of lysates were analyzed by Western blot analysis
using antibodies against p-JAK1(Tyr1022/1023), JAK1, p-JAK2(Tyr1007/1008), JAK2, p-Src(Tyr416), and Src. The results shown here are representative of
three independent experiments. c Pervanadate reverses the p-STAT3 inhibitory effect of RES. Caki-1 and 786-O cells (1 × 106 cells/well) were co-
incubated with the indicated concentrations of pervanadate and 50 μM RES for 6 h, after which whole-cell extracts were prepared and 15 μg portions
of those extracts were resolved on 8 % SDS-PAGE gel, electrotransferred onto nitrocellulose membranes, and probed for p-STAT3(Tyr705) and STAT3.
d Caki-1 and 786-O cells (1 × 106 cells/well) were treated with various indicated concentrations of RES for 6 h, after which whole-cell extracts were
prepared and 10 μg portions of those extracts were resolved on 8 % SDS-PAGE, electrotransferred onto nitrocellulose membranes, probed for PTPε and
SHP-2 antibody. The same blots were stripped and reprobed with β-actin antibody to verify equal protein loading. e Caki-1 and 786-O cells (1 × 106
cells/well) were treated with various indicated concentrations of RES for 6 h, and total RNA was extracted and examined for expression of PTPε C, PTPε
M, and SHP-2 by RT-PCR. GAPDH was used as an internal control to show equal RNA loading. f Effect of PTPε knockdown on RES induced expression of
PTPε. Caki-1 cells were transfected with either PTPε siRNA or scrambled siRNA (50 nM). After 48 h, cells were treated with 50 μM RES for 6 h and whole-
cell extracts were subjected to Western blot analysis (left panels). Effect of SHP-2 knockdown on RES induced expression of SHP-2. 786-O cells were
transfected with either SHP-2 siRNA or scrambled siRNA (50 nM). After 48 h, cells were treated with 50 μM RES for 6 h and whole-cell extracts were
subjected to Western blot analysis (right panels)
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dependent manner (Fig. 1e and f). These results show
that RES abrogates the DNA binding ability of STAT3
and STAT5.
RES reduces nuclear pool of STAT3 and STAT5 in renal
cell carcinoma
We next analyzed whether RES can suppress nuclear
translocation of STAT3 and STAT5 in RCC cells.
Figure 1g and h clearly demonstrates that RES re-
duced the translocation of STAT3 and STAT5 to the
nucleus in both Caki-1 and 786-O cells.
RES inhibits activation of upstream kinases involved in
STAT3/5 signaling cascade in RCC cells
In order to determine which upstream signaling molecules
are involved in RES-mediated STAT3/5 inactivation, we
examined the effects of RES on the phosphorylation of
JAK1, JAK2, and Src in Caki-1 and 786-O cells. Cells were
treated with the indicated concentrations of RES for
6 h. As shown in Fig. 2a, JAK1 and JAK2 were constitu-
tively active in Caki-1 and 786-O cells and the treat-
ment with RES clearly suppressed its phosphorylation
in a concentration-dependent manner. The levels of
total JAK1/2 remained unchanged under the same con-
ditions (Fig. 2a, second and fourth panels).
We also determined the effect of RES on constitutive
activation of Src kinase in both Caki-1 and 786-O cells.
Interestingly, RES suppressed the constitutive phosphor-
ylation of Src kinase in a concentration-dependent man-
ner in these cells (Fig. 2b).
Tyrosine phosphatases are involved in RES-induced
inhibition of STAT3 activation
To analyze whether RES-induced inhibition of STAT3
phosphorylation could be due to activation of a protein
tyrosine phosphatase (PTPase), Caki-1 and 786-O cells
were treated with the broad-acting tyrosine phosphatase
inhibitor sodium pervanadate. We noted that preventedthe RES-induced inhibition of STAT3 activation (Fig. 2c).
This data suggests that tyrosine phosphatases may be in-
volved in RES-induced inhibition of STAT3 activation in
RCC cells.
RES induces the expression of PTPε and SHP-2 in RCC
cells
Protein tyrosine phosphatases have been also implicated
in the STATs signaling pathways [45]. Thus, we exam-
ined whether RES regulates the expression of PTPε, and
SHP-2, which are non-transmembrane PTPs expressed
most abundantly in hematopoietic cells [36, 37, 46, 47].
As shown in Fig. 2d, RES led to increased expression of
PTPε in Caki-1 cells, and SHP-2 in 786-O at the protein
level. RES also enhanced mRNA level of PTPε C and
SHP-2 in a dose dependent manner in Caki-1 and 786-
O cells (Fig. 4e).
PTPε siRNA down-regulate the expression of PTPε and
reverses the inhibition of STAT3 activation by RES in
Caki-1 cells
We determined whether the suppression of PTPε ex-
pression by siRNA would abrogate the inhibitory effect
of RES on STAT3 activation in Caki-1 cells. Western
blotting showed that RES-induced PTPε expression was
effectively abolished in the cells treated with PTPε
siRNA; whereas treatment with scrambled siRNA had
no effect (Fig.2f, left, first panel). We also found that
RES did not suppress STAT3 activation in cells treated
with PTPε siRNA (Fig. 2f, left, third panel).
SHP-2 siRNA down-regulate the expression of SHP-2 and
reverses the inhibition of STAT3 activation by RES in
786-O cells
We also determined whether the deletion of SHP-2 ex-
pression by siRNA would abolish the suppressive effect
of RES on STAT3 activation in 786-O cells. We found
that RES-induced SHP-2 expression was effectively pre-
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Fig. 3 RES causes the accumulation of cells in S phase, induces apoptosis, and suppresses colony forming ability in renal cell carcinoma. a Caki-1
and 786-O cells (1 × 106 cells/well) were treated with 50 μM of RES for 24 h. Then, the cells were fixed and analyzed using a flow cytometry. The
results shown here are representative of three independent experiments. b Caki-1 and 786-O cells (1 × 106 cells/well) were treated with 50 μM of
RES for 24 h. Afterward, the cells were incubated with anti-Annexin V antibody conjugated with FITC plus PI and analyzed with a flow cytometer
for apoptotic effects. The results shown here are representative of three independent experiments. c Two cells (1 × 106 cells/well) were treated
with RES at 50 μM concentrations for 24 h and the cells were incubated with TMRE (tetramethylrhodamine, ethyl ester) and then analyzed by a
flow cytometry. The results shown here are representative of three independent experiments. d Caki-1 and 786-O cells were incubated with RES
and subsequently allowed to grow into colonies. After 14 days incubation, cells were fixed with 10 % formalin and stained with crystal violet
reagent, photographed and colonies were counted and represented graphically. Results are representative of two independent experiments
Kim et al. BMC Nephrology  (2016) 17:19 Page 8 of 13with scrambled siRNA had no effect (Fig. 2f, right, first
panel). RES did not suppress STAT3 activation in cells
treated with SHP-2 siRNA (Fig. 2f, right, third panel).
RES induces S phase cell cycle arrest in renal cell
carcinoma
We also examined the effects of RES on cell cycle pro-
gression in Caki-1 and 786-O cells. As shown in Fig. 3a,
RES-induced an increased accumulation of the cell
population in S phase and a corresponding decrease of
cells in the G1/G0 phases on Caki-1 and 786-O cells.
RES promotes substantial apoptosis in renal cell
carcinoma
To evaluate the anti-cancer effects of RES, we also ex-
amined the apoptosis-inducing effects of RES by using
the Annexin V assay. The Annexin V positive cells were
increased as compared with the non-treated cells and
Annexin V-FITC and PI positive cells were also in-
creased in Caki-1 and 786-O cells (Fig. 3b).
RES causes loss of mitochondrial membrane potential in
RCC cells
We also examined whether RES induces changes in the
mitochondrial membrane potential in Caki-1 and 786-
Ocells. TMRE is a cell permeable, positively-charged,
red-orange dye that readily accumulates in active mito-
chondria due to their relative negative charge. Depolar-
ized or inactive mitochondria have decreased membrane
potential and fail to sequester TMRE. As shown in
Fig. 3c, the accumulation of TMRE labeled mitochon-
dria was notably reduced on RES treatment for 24 h as
compared with the non-treated cells. These results sug-
gest that RES induces both early and late apoptosis ac-
companied with mitochondrial dysfunction in these
RCC cells.
RES suppresses colony formation of RCC cells
A clonogenic assay evaluates the potential of a single cell
to resist treatments and grow into a colony [48]. The in-
fluence of RES on the clonogenic capacity of Caki-1 and
786-O cells was also evaluated. RES significantly inhib-
ited colony formation and resulted in a remarkable de-
crease at colony formation ratio (Fig. 3d).RES represses the expression of various proteins involved
in anti-apoptosis, proliferation, and angiogenesis
Because bcl-2, bcl-xL, survivin, IAP-1, and IAP-2 have
been implicated in apoptosis and mitochondrial dysfunc-
tion, we next examined the effects of RES on the consti-
tutive expression of these proteins by Western blot
analysis. Cells were treated with 10, 30, or 50 μM of RES
for 24 h. We observed that the constitutive expression
of bcl-xl, bcl-2, survivin, IAP-1, and IAP-2 was dose-
dependently reduced in RES-treated cells. Also, RES
suppressed proteins linked with cell proliferation (COX-
2), and angiogenesis (VEGF, and MMP-9) (Fig. 4a).
RES activates caspase-3 and causes PARP cleavage
Whether suppression of constitutively active STAT3 in
Caki-1 and 786-O cells by RES leads to apoptosis was
also investigated. In these RCC cells treated with RES
there was a dose-dependent activation of pro-caspase-3
and increased expression of cleaved caspase-3. Caki-1 and
786-O cells were treated with indicated concentration of
RES for the 24 h, and then examined for caspase activa-
tion by Western blot using specific antibodies. We found
a dose-dependent activation of caspase-3 by RES in these
RCC cell lines (Fig. 4b, first panel). Activation of down-
stream caspases led to the cleavage of a 116 kDa PARP
protein into 87 kDa fragments (Fig. 4b, Second panel).
Taken together, these results suggest that RES induces
caspase-3-dependent apoptosis in Caki-1 and 786-Ocells.
RES alters the expression of cell cycle-associated proteins
We also investigated whether RES blocks expression of
various cell cycle associated proteins. As shown in
Fig. 4c, RES induced a dose-dependent decrease in cyc-
lin D1 and cyclin E protein levels, while an increased ex-
pression of p21 was observed after RES treatment
(Fig. 4c, third panel). Taken together, these results indi-
cate that RES decreased growth by blocking cell cycle
progression via the upregulation of p21 and/or the
downregulation of cyclin D1 and cyclin E expression.
RES induces the expression of both Bax and p53 in RCC
cells
To determine whether RES induces expression of Bax
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Fig. 4 RES suppresses expression of various proteins involved in anti-apoptosis, proliferation, and angiogenesis. a-d After Caki-1 and 786-O cells
(1 × 106 cells/well) were incubated with the indicated various concentrations of RES for 24 h. Whole-cell extracts were prepared, and 20 μg of the
whole-cell lysate was resolved by SDS-PAGE, electrotransferred to nitrocellulose membrane, and then probed with antibodies against bcl-2, bcl-xL,
survivin, IAP1/2, COX-2, VEGF, MMP-9, caspase-3, PARP, cyclin D1, cyclin E, p21, Bax, and p53 as described in “Materials and methods.” The
same blots were stripped and reprobed with β-actin antibody to verify equal protein loading. The results shown here are representative of
three independent experiments. e Cell proliferation assay was performed using the Roche xCELLigence Real-Time Cell Analyzer (RTCA) DP
instrument (Roche Diagnostics GmbH, Germany) as described in “Material and methods”. After Caki-1 and 786-O cells (5 × 103 cells/well) were
seeded onto 16-well E-plates and continuously monitored using impedance technology. f Caki-1 and 786-O cells were added to the upper
side of the invasion chamber, the cells on the upper surface of the filter were removed after 24 h of incubation in the presence or absence of
10 μM of RES. The cells on the lower surface were fixed, stained and monitored by photographing, then counted. Randomly chosen fields
were photographed under a light microscope at 100× magnification and invaded cells were counted
Kim et al. BMC Nephrology  (2016) 17:19 Page 10 of 13in Caki-1 and 786-O cells by Western blot analysis.
Figure 4d shows that RES induced the expression of
Bax and p53 gene products in a dose-dependent
manner.
RES significantly suppresses the viability of RCC cells
To specifically examine the anti-tumor activity of RES
on Caki-1 and 786-O cells, the cells were treated with
30 or 50 μM concentrations of RES, and then cell viabil-
ity was analyzed every 15 min time intervals using the
xCELLigence RTCA DP Instrument (Roche Diagnostics
GmbH, Germany). As shown in Fig. 4e, RES significantly
suppressed cell proliferation in RCC cells in a time-
dependent manner.
RES inhibits the invasion of RCC cells
Cyclin D1 and VEGF, all regulated by STAT3, are major
players in tumor metastasis and has been shown to me-
diate tumor invasion [49–51]. Whether RES can modu-
late tumor cell invasion activity was investigated in vitro.
To determine this, Caki-1 and 786-O cells were analyzed
by Boyden chamber assay. We found that these cells ex-
hibited a very high invasive potential through a thick
layer of Matrigel, and this invasive ability was signifi-
cantly attenuated by RES (Fig. 4f ).
RES enhances the effect of sorafenib on induction of
apoptosis in 786-O cells
Sorafenib (a kinase inhibitor) has been used for treating
renal cell carcinoma patients. To determine whether
RES potentiates the apoptotic effect of sorafenib, we
treated 786-O cells with RES combined with sorafenib,
and then examined the cell viability with a MTT assay.
We found that RES indeed enhanced the cytotoxic ef-
fects of sorafenib using CalcuSynsoftware (BIOSOFT,
Ferguson, MO) (Fig. 5a). Also, we further examined
whether RES can potentiate the inhibitory effect of so-
rafenib on constitutive STAT3 and STAT5 phosphoryl-
ation in 786-O cells by Western blot analysis. As shown
in Fig. 5b, RES substantially enhanced the inhibitory ef-
fects of sorafenib on phosphorylated STAT3 and STAT5
in 786-O cells. Interestingly, RES or sorafenib alone atsub-optimal concentrations had little effect on levels of
bcl-2, bcl-xl, and surviving proteins in 786-O cells. How-
ever, treatment of cells with the combination of RES and
sorafenib resulted in a marked attenuation in the expres-
sion levels of all of these proteins (Fig. 4c). Caspase-3
and PARP cleavage were further increased by the co-
treatment of RES along with sorafenib rather than indi-
vidual agents alone in 786-O cells (Fig. 5d). Overall,
these results indicate that RES can significantly enhance
the apoptotic effect of sorafenib in 786-O cells through
the downregulation of various cell survival proteins.
Discussion
Although RES has been reported to suppress the prolif-
eration of a wide variety of tumor cell types and induce
apoptosis, the mechanism is not yet fully understood in
renal cell carcinoma. The aim of the present study was
to determine the effect of RES on the STAT3 and STAT5
signaling pathways in two kinds of RCC cells. We found
that this polyphenol phytoalexin suppressed constitutive
STAT3 (tyrosine residue 705 and serine residue 727) and
STAT5 (tyrosine residue 694 and 699) activation in RCC
in parallel with the inhibition of JAK1, JAK2, and c-Src
activation. We further found that RES induced the ex-
pression of protein tyrosine phosphatases such as PTPε
and SHP-2 in Caki-1 and 786-O cells, respectively. RES
down-regulated the expression of various oncogenic
genes, caused the inhibition of proliferation, increased
accumulation of cells in S phase, suppressed invasive
and colony formation activity, and significantly potenti-
ated the apoptotic effects of sorafenib in RCC cells.
We found for the first time that RES could suppress
constitutive STAT3 phosphorylation both at Tyr705 and
Ser727, in Caki-1 and 786-O cells. Furthermore, RES
had effect on STAT5 phosphorylation at Tyr 694/Tyr
699 residue. We also observed that RES suppressed
DNA-binding activity and nuclear translocation of both
STAT3 and STAT5. We also observed that RES inhibited
the activation of constitutively active JAK1, JAK2, and
Src kinases in RCC cells. JAKs are essential for the tyro-
sine phosphorylation of STAT3/5 in response to growth
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Fig. 5 RES potentiates the cytotoxic and apoptotic effects of sorafenib in renal cell carcinoma. a and b Caki-1 and 786-O cells (5× 103 cells/well)
were treated with indicated concentration of RES, and sorafenib for 24 h. The cytotoxicity was determined by MTT assays (left panel). The combination
index (CI) values were obtained using BiosoftCalcuSyn software (Biosoft, Cambridge, UK) (right panel). c Caki-1 and 786-O cells (1 × 106 cells/well) were
treated with indicated concentration of RES, and sorafenibfor6h. After which whole-cell extracts were prepared and 15 μg portions of those extracts
were resolved on 8 % SDS-PAGE gel, electrotransferred onto nitrocellulose membranes, and probed against p-STAT3(Tyr705), p-STAT3(Ser727), STAT3,
p-STAT5(Tyr694/699), and STAT5. The results shown here are representative of three independent experiments. d and e Caki-1 and 786-O cells (1 × 106
cells/well) were treated with indicated concentration of RES, and sorafenibfor24h. Whole-cell extracts were prepared, and 20 μg of the whole-cell lysate
was resolved by SDS-PAGE, electrotransferred to nitrocellulose membrane, and then probed with antibodies against bcl-2, bcl-xL, survivin, caspase-3,
and PARP. The same blots were stripped and reprobed with β-actin antibody to verify equal protein loading
Kim et al. BMC Nephrology  (2016) 17:19 Page 11 of 13phosphorylation clearly plays a pivotal role in the prolif-
eration and survival of a wide variety of tumor cells and
that blockade of JAK/STATs signals can provide a potent
therapeutic strategy for RCC [13, 34, 35, 53].We also found evidence that the RES-induced inhib-
ition of STAT3 activation involves a protein tyrosine
phosphatase (PTP). Various PTPs have been shown to
play an important role in STAT3 signaling, including
Kim et al. BMC Nephrology  (2016) 17:19 Page 12 of 13SHP-1 [54], SHP-2 [55], T-cell PTP [56], PTEN [57],
PTP-1D [58], CD45 [59], PTPε [60], and low molecular
weight PTP [61, 62].
Indeed, we found for the first time that RES stimulates
the expression of PTPε proteins and mRNAs in Caki-1
cells, and induces the expression of SHP-2 proteins and
mRNAs in 786-O cells, which correlated with down-
regulation of constitutive STAT3/JAK1/2 and Src phos-
phorylation in these cell lines. Transfection with PTPε
and SHP-2siRNA reversed the STAT3 inhibitory effect
of RES, thereby further implicating a critical role of
these two phosphatases in RES-induced down-regulation
of STAT3 signaling cascade.
We further observed that RES can suppress the ex-
pression of several STAT3/5-regulated genes; including
antiapoptotic gene products (bcl-xl, bcl-2, IAP-1/2, and
survivin), cell proliferation (COX-2), inducers of angio-
genesis (MMP-9 and VEGF), and cell-cycle regulators
(cyclin D1, and cyclin E). Activation of constitutive
STAT3/5 can affect to oncogenesis by protecting cancer
cells from apoptosis; this implies that suppression of
STAT3 activation by agents such as RES could facilitate
apoptosis.
The down-regulation of the expression of bcl-2, bcl-xl,
and survivin is likely linked with the ability of RES to in-
duce apoptosis in RCC. Inhibition of MMP-9 expression
by RES correlated with its observed significant anti-
invasive effects in the cells. Recently, sorafenib (a kinase
inhibitor) has been approved for treating renal cell car-
cinoma patients [63]. We further found that RES can
significantly enhance the apoptotic effects of sorafenib
in RCC cells through the downregulation of various
STAT3-regulated proteins and hence could also be used
in conjunction with existing anti-RCC therapies.Conclusions
Overall, our experimental findings clearly indicate that
the pro-apoptotic and anti-invasive effects of RES medi-
ated through the suppression of STAT3/5 activation cas-
cade and its-regulated oncogenic gene products in RCC.
Taken together, these results may provide new mechanistic
insights into the anti-cancer actions of this phytoalexin.
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